NASDAQ:KIN - Kindred Biosciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$9.85 -0.10 (-1.01 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$9.85
Today's Range$9.65 - $10.05
52-Week Range$6.55 - $10.15
Volume135,614 shs
Average Volume132,028 shs
Market Capitalization$280.62 million
P/E Ratio-8.01
Dividend YieldN/A
Beta0.08

About Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences logoKindred Biosciences, Inc., a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs related to equine metabolic syndrome. It is also developing biologics programs, including KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) to treat newborn foals; and canine atopic dermatitis, an immune-mediated inflammatory, chronic skin disease related to allergies. In addition, the company engages in the development of other biologic product candidates, such as KIND-502 to treat allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a biologics scaffold technology. Further, it is developing anti-IL31, anti-IL17, and anti-IL4/13 sink antibodies for treating atopic dermatitis in dogs; anti-TNF antibody for inflammatory bowel disease in dogs; anti-IgE antibody for treating allergic diseases in dogs; anti-VEGF antibody for cancer in dogs; anti-CD20 for treating cancer and autoimmune diseases in dogs; and checkpoint inhibitors to treat cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901

Debt

Debt-to-Equity RatioN/A
Current Ratio18.56
Quick Ratio18.56

Price-To-Earnings

Trailing P/E Ratio-8.01
Forward P/E Ratio-6.35
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book3.65

Profitability

EPS (Most Recent Fiscal Year)($1.23)
Net Income$-30,870,000.00
Net MarginsN/A
Return on Equity-41.64%
Return on Assets-39.66%

Miscellaneous

Employees63
Outstanding Shares28,200,000

Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences (NASDAQ:KIN) issued its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.36). View Kindred Biosciences' Earnings History.

What price target have analysts set for KIN?

7 equities research analysts have issued 12-month price targets for Kindred Biosciences' stock. Their predictions range from $10.50 to $16.75. On average, they expect Kindred Biosciences' share price to reach $12.5625 in the next year. View Analyst Ratings for Kindred Biosciences.

Who are some of Kindred Biosciences' key competitors?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:
  • Dr. Richard Chin, Co-Founder, Pres, CEO & Director (Age 51)
  • Ms. Denise M. Bevers, Co-Founder, Chief Operating Officer and Sec. (Age 51)
  • Ms. Wendy K. Wee, CFO & Principal Accounting Officer (Age 65)
  • Dr. Hangjun Zhan, Chief Scientific Officer
  • Dr. Noe Reyes D.V.M, Medical Director

Has Kindred Biosciences been receiving favorable news coverage?

Media headlines about KIN stock have been trending somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kindred Biosciences earned a daily sentiment score of 0.11 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 47.50 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Kindred Biosciences' major shareholders?

Kindred Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (4.84%), BlackRock Inc. (3.91%), General American Investors Co. Inc. (2.12%), Wells Fargo & Company MN (1.28%), New York State Common Retirement Fund (0.86%) and B. Riley Financial Inc. (0.46%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

Which institutional investors are selling Kindred Biosciences stock?

KIN stock was sold by a variety of institutional investors in the last quarter, including Amtrust Financial Services Inc., General American Investors Co. Inc., BlackRock Inc. and Wells Fargo & Company MN. Company insiders that have sold Kindred Biosciences company stock in the last year include Raymond Townsend and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.

Which institutional investors are buying Kindred Biosciences stock?

KIN stock was bought by a variety of institutional investors in the last quarter, including B. Riley Financial Inc., Citigroup Inc., New York State Common Retirement Fund and Dimensional Fund Advisors LP. View Insider Buying and Selling for Kindred Biosciences.

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $9.85.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $280.62 million. The biopharmaceutical company earns $-30,870,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Kindred Biosciences employs 63 workers across the globe.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]


MarketBeat Community Rating for Kindred Biosciences (KIN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kindred Biosciences (NASDAQ:KIN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Kindred Biosciences in the last 12 months. Their average twelve-month price target is $12.5625, suggesting that the stock has a possible upside of 27.54%. The high price target for KIN is $16.75 and the low price target for KIN is $10.50. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.672.673.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $12.5625$10.10$9.90$9.80
Price Target Upside: 27.54% upside13.48% upside3.13% upside33.33% upside

Kindred Biosciences (NASDAQ:KIN) Consensus Price Target History

Price Target History for Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences (NASDAQ:KIN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018EuroPacific CanadaInitiated CoverageBuy$16.75LowView Rating Details
5/9/2018HC WainwrightBoost Price TargetBuy$12.00MediumView Rating Details
12/27/2017CL KingInitiated CoverageNeutral ➝ NeutralLowView Rating Details
12/22/2017BMO Capital MarketsReiterated RatingHoldHighView Rating Details
12/15/2017AegisReiterated RatingBuyLowView Rating Details
12/5/2017B. RileySet Price TargetBuy$11.00LowView Rating Details
5/31/2017FBR & CoReiterated RatingBuyLowView Rating Details
1/3/2017Feltl & Co.Reiterated RatingStrong-BuyN/AView Rating Details
11/1/2016Ladenburg ThalmannInitiated CoverageBuy$7.50N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Kindred Biosciences (NASDAQ:KIN) Earnings History and Estimates Chart

Earnings by Quarter for Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences (NASDAQ:KIN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.57)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.33)($0.33)($0.33)
Q2 20181($0.42)($0.42)($0.42)
Q3 20181($0.45)($0.45)($0.45)
Q4 20181($0.37)($0.37)($0.37)

Kindred Biosciences (NASDAQ KIN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.36)($0.36)ViewN/AView Earnings Details
3/1/2018Q4 2017($0.33)($0.35)ViewListenView Earnings Details
11/7/2017Q3 2017($0.33)($0.29)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.33)($0.29)ViewListenView Earnings Details
5/4/2017Q1 2017($0.34)($0.30)ViewListenView Earnings Details
3/1/2017Q416($0.36)($0.29)ViewListenView Earnings Details
11/7/2016Q316($0.36)($0.29)ViewListenView Earnings Details
8/8/2016Q216($0.32)($0.25)ViewN/AView Earnings Details
5/5/2016Q1 2016($0.28)($0.31)ViewN/AView Earnings Details
3/2/2016Q415($0.44)($0.32)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.44)($0.36)ViewN/AView Earnings Details
8/10/2015Q2($0.42)($0.35)ViewN/AView Earnings Details
5/8/2015Q115($0.40)($0.34)ViewN/AView Earnings Details
3/12/2015Q414($0.40)($0.34)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.43)($0.31)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.35)($0.42)ViewN/AView Earnings Details
5/12/2014Q1 14($0.18)($0.38)ViewN/AView Earnings Details
3/6/2014($0.21)($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Kindred Biosciences (NASDAQ:KIN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Kindred Biosciences (NASDAQ KIN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.96%
Institutional Ownership Percentage: 62.42%
Insider Trading History for Kindred Biosciences (NASDAQ:KIN)
Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences (NASDAQ KIN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2018Richard ChinInsiderSell2,400$10.00$24,000.002,241,741View SEC Filing  
5/9/2018Richard ChinInsiderSell1,930$10.01$19,319.302,244,341View SEC Filing  
5/7/2018Richard ChinCEOSell1,730$10.01$17,317.302,244,341View SEC Filing  
5/1/2018Richard ChinInsiderSell20,000$9.05$181,000.002,246,071View SEC Filing  
4/2/2018Richard ChinInsiderSell20,000$8.39$167,800.002,266,071View SEC Filing  
3/16/2018Raymond TownsendDirectorSell2,670$9.45$25,231.5025,057View SEC Filing  
3/12/2018Raymond TownsendDirectorSell91$9.45$859.9523,233View SEC Filing  
1/2/2018Raymond TownsendDirectorSell6,419$9.45$60,659.5518,419View SEC Filing  
7/12/2017Park West Asset Management LlcMajor ShareholderBuy600,000$7.50$4,500,000.00View SEC Filing  
7/3/2017Richard ChinInsiderSell13,000$8.26$107,380.002,297,546View SEC Filing  
6/22/2017Richard ChinInsiderSell13,000$7.75$100,750.002,310,546View SEC Filing  
6/8/2017Park West Asset Management LlcMajor ShareholderBuy15,311$6.65$101,818.15View SEC Filing  
5/11/2017Park West Asset Management LlcMajor ShareholderBuy155,076$6.83$1,059,169.08View SEC Filing  
3/15/2017Park West Asset Management LlcMajor ShareholderBuy400,000$6.60$2,640,000.00View SEC Filing  
3/13/2017Park West Asset Management LlcMajor ShareholderBuy4,200$6.20$26,040.00View SEC Filing  
3/9/2017Park West Asset Management LlcMajor ShareholderBuy18,066$6.08$109,841.28View SEC Filing  
1/13/2017Park West Asset Management LlcMajor ShareholderBuy1,690,000$6.20$10,478,000.00View SEC Filing  
1/9/2017Park West Asset Management LlcMajor ShareholderBuy131,500$5.30$696,950.00View SEC Filing  
1/6/2017Park West Asset Management LlcMajor ShareholderBuy110,617$5.10$564,146.70View SEC Filing  
12/16/2016Park West Asset Management LlcInsiderSell18,000$4.78$86,040.00View SEC Filing  
12/14/2016Park West Asset Management LlcMajor ShareholderBuy8,334$4.75$39,586.50View SEC Filing  
12/13/2016Park West Asset Management LlcMajor ShareholderBuy1,148$4.75$5,453.00View SEC Filing  
12/12/2016Park West Asset Management LlcMajor ShareholderBuy3,112$4.74$14,750.88View SEC Filing  
3/15/2016Ernest MarioDirectorBuy30,000$3.55$106,500.0099,583View SEC Filing  
11/23/2015Raymond TownsendDirectorBuy2,000$4.00$8,000.0012,000View SEC Filing  
11/18/2015Raymond TownsendDirectorBuy2,323$4.78$11,103.9410,000View SEC Filing  
8/31/2015Raymond TownsendDirectorBuy1,677$5.85$9,810.457,677View SEC Filing  
8/14/2015Raymond TownsendDirectorBuy3,000$6.04$18,120.00View SEC Filing  
9/29/2014Oleg NodelmanDirectorBuy100,000$9.56$956,000.00View SEC Filing  
9/3/2014Ernest MarioDirectorBuy10,000$10.55$105,500.00View SEC Filing  
8/28/2014Oleg NodelmanDirectorBuy47,000$10.85$509,950.00View SEC Filing  
8/26/2014Oleg NodelmanDirectorBuy85,244$10.50$895,062.00View SEC Filing  
12/12/2013Kevin SchultzInsiderBuy4,000$7.00$28,000.00View SEC Filing  
12/12/2013Oleg NodelmanDirectorBuy400,000$7.00$2,800,000.00View SEC Filing  
12/12/2013Stephen SundlofSVPBuy1,000$7.00$7,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Kindred Biosciences (NASDAQ KIN) News Headlines

Source:
DateHeadline
Kindred Biosciences (KIN) Now Covered by Analysts at EuroPacific CanadaKindred Biosciences (KIN) Now Covered by Analysts at EuroPacific Canada
www.americanbankingnews.com - May 23 at 4:19 PM
Kindred Biosciences (KIN) Insider Richard Chin Sells 2,400 SharesKindred Biosciences (KIN) Insider Richard Chin Sells 2,400 Shares
www.americanbankingnews.com - May 18 at 8:53 PM
Zacks: Brokerages Expect Kindred Biosciences (KIN) Will Announce Earnings of -$0.39 Per ShareZacks: Brokerages Expect Kindred Biosciences (KIN) Will Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - May 13 at 11:14 PM
Kindred Biosciences (KIN) Stock Rating Lowered by Zacks Investment ResearchKindred Biosciences (KIN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 12 at 10:39 AM
Form 4 Kindred Biosciences, For: Feb 15 Filed by: Park West Asset Management LLCForm 4 Kindred Biosciences, For: Feb 15 Filed by: Park West Asset Management LLC
www.streetinsider.com - May 12 at 10:23 AM
Edited Transcript of KIN earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of KIN earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 4:18 PM
Kindred Biosciences (KIN) CEO Richard Chin on Q1 2018 Results - Earnings Call TranscriptKindred Biosciences' (KIN) CEO Richard Chin on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 10:42 AM
Q2 2018 EPS Estimates for Kindred Biosciences (KIN) Reduced by AnalystQ2 2018 EPS Estimates for Kindred Biosciences (KIN) Reduced by Analyst
www.americanbankingnews.com - May 11 at 9:41 AM
Kindred Biosciences Target of Unusually High Options Trading (KIN)Kindred Biosciences Target of Unusually High Options Trading (KIN)
www.americanbankingnews.com - May 11 at 8:15 AM
Kindred Biosciences (KIN) Receives Average Recommendation of "Buy" from BrokeragesKindred Biosciences (KIN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 10 at 7:37 PM
Unlocking The Value In Animal MedicineUnlocking The Value In Animal Medicine
finance.yahoo.com - May 10 at 9:53 AM
Kindred Biosciences (KIN) Releases  Earnings Results, Meets ExpectationsKindred Biosciences (KIN) Releases Earnings Results, Meets Expectations
www.americanbankingnews.com - May 9 at 10:28 PM
Kindred Biosciences (KIN) CEO Richard Chin Sells 1,730 SharesKindred Biosciences (KIN) CEO Richard Chin Sells 1,730 Shares
www.americanbankingnews.com - May 9 at 10:15 PM
Kindred Biosciences (KIN) Insider Richard Chin Sells 1,930 SharesKindred Biosciences (KIN) Insider Richard Chin Sells 1,930 Shares
www.americanbankingnews.com - May 9 at 10:14 PM
Kindred Biosciences (KIN) Price Target Increased to $12.00 by Analysts at HC WainwrightKindred Biosciences (KIN) Price Target Increased to $12.00 by Analysts at HC Wainwright
www.americanbankingnews.com - May 9 at 4:43 PM
FDA Approves Kindred Bio’s Drug To Treat Weight Loss In CatsFDA Approves Kindred Bio’s Drug To Treat Weight Loss In Cats
www.bloomberg.com - May 9 at 4:20 PM
BRIEF-Kindred Biosciences Reports Q1 Loss Per Share $0.36BRIEF-Kindred Biosciences Reports Q1 Loss Per Share $0.36
www.reuters.com - May 9 at 9:42 AM
Blog Exposure - Kindred Biosciences Gets FDA Approval for MiratazBlog Exposure - Kindred Biosciences Gets FDA Approval for Mirataz
finance.yahoo.com - May 9 at 9:42 AM
Kindred Biosciences Announces First Quarter 2018 Financial ResultsKindred Biosciences Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 4:18 PM
Is Prima Park SA. (WSE:KIN) A Financially Sound Company?Is Prima Park SA. (WSE:KIN) A Financially Sound Company?
finance.yahoo.com - May 8 at 4:18 PM
This Peninsula company's new drug is the cat's meow — the FDA says soThis Peninsula company's new drug is the cat's meow — the FDA says so
finance.yahoo.com - May 8 at 9:35 AM
BRIEF-Kindred Biosciences Says Entered Into At Market Issuance Sales AgreementBRIEF-Kindred Biosciences Says Entered Into At Market Issuance Sales Agreement
www.reuters.com - May 7 at 9:29 AM
Form 424B5 Kindred Biosciences,Form 424B5 Kindred Biosciences,
www.streetinsider.com - May 7 at 9:29 AM
Weight Gain Season for FelinesWeight Gain Season for Felines
finance.yahoo.com - May 7 at 9:29 AM
Kindred Biosciences Receives FDA Approval of Mirataz™ (mirtazapine transdermal ointment) for the Management of Weight Loss in CatsKindred Biosciences Receives FDA Approval of Mirataz™ (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats
www.prnewswire.com - May 7 at 7:12 AM
Kindred Biosciences (KIN) Upgraded to "Hold" by Zacks Investment ResearchKindred Biosciences (KIN) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - May 5 at 6:37 AM
Insider Selling: Kindred Biosciences (KIN) Insider Sells 20,000 Shares of StockInsider Selling: Kindred Biosciences (KIN) Insider Sells 20,000 Shares of Stock
www.americanbankingnews.com - May 2 at 10:30 PM
Kindred Biosciences (KIN) Scheduled to Post Quarterly Earnings on TuesdayKindred Biosciences (KIN) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 10:13 AM
 Brokerages Expect Kindred Biosciences (KIN) Will Announce Earnings of -$0.38 Per Share Brokerages Expect Kindred Biosciences (KIN) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - April 26 at 11:51 AM
Kindred Biosciences (KIN) Provides Updates on Pending Drug ApprovalsKindred Biosciences (KIN) Provides Updates on Pending Drug Approvals
www.streetinsider.com - April 25 at 4:28 PM
Kindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of DirectorsKindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of Directors
finance.yahoo.com - April 25 at 4:28 PM
Kindred Biosciences Provides Updates on Pending Drug ApprovalsKindred Biosciences Provides Updates on Pending Drug Approvals
finance.yahoo.com - April 24 at 4:30 PM
Kindred Biosciences to Announce First Quarter 2018 Financial ResultsKindred Biosciences to Announce First Quarter 2018 Financial Results
finance.yahoo.com - April 18 at 4:32 PM
Kindred Biosciences (KIN) Upgraded to "Buy" at ValuEngineKindred Biosciences (KIN) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 17 at 10:29 AM
Kindred Biosciences (KIN) Given Average Rating of "Hold" by AnalystsKindred Biosciences (KIN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 15 at 7:31 PM
Kindred Biosciences (KIN) Rating Increased to Buy at BidaskClubKindred Biosciences (KIN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 10:43 AM
Kindred Biosciences (KIN) Upgraded to Buy at Zacks Investment ResearchKindred Biosciences (KIN) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - April 13 at 1:35 PM
-$0.38 EPS Expected for Kindred Biosciences Inc (KIN) This Quarter-$0.38 EPS Expected for Kindred Biosciences Inc (KIN) This Quarter
www.americanbankingnews.com - April 9 at 1:21 PM
Kindred Biosciences (KIN) Upgraded to Buy by Zacks Investment ResearchKindred Biosciences (KIN) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 9 at 12:10 PM
Kindred Biosciences (KIN) Downgraded by Zacks Investment Research to "Hold"Kindred Biosciences (KIN) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 9 at 8:37 AM
Kindred Biosciences (KIN) Downgraded to "Hold" at Zacks Investment ResearchKindred Biosciences (KIN) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 7 at 2:14 PM
Richard Chin Sells 20,000 Shares of Kindred Biosciences Inc (KIN) StockRichard Chin Sells 20,000 Shares of Kindred Biosciences Inc (KIN) Stock
www.americanbankingnews.com - April 4 at 11:16 PM
Kindred Biosciences (KIN) Downgraded by ValuEngineKindred Biosciences (KIN) Downgraded by ValuEngine
www.americanbankingnews.com - March 31 at 12:42 PM
Kindred Biosciences (KIN) Downgraded by Zacks Investment Research to "Sell"Kindred Biosciences (KIN) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 30 at 11:10 PM
Kindred Biosciences (KIN) Rating Lowered to Sell at Zacks Investment ResearchKindred Biosciences (KIN) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 10:54 AM
Kindred Biosciences Inc (KIN) Given Consensus Recommendation of "Hold" by AnalystsKindred Biosciences Inc (KIN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 21 at 7:36 PM
Kindred Biosciences Inc (KIN) Director Raymond Townsend Sells 2,670 SharesKindred Biosciences Inc (KIN) Director Raymond Townsend Sells 2,670 Shares
www.americanbankingnews.com - March 19 at 8:30 PM
Kindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare ConferenceKindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 8 at 5:05 PM
 Brokerages Expect Kindred Biosciences Inc (KIN) Will Announce Earnings of -$0.38 Per Share Brokerages Expect Kindred Biosciences Inc (KIN) Will Announce Earnings of -$0.38 Per Share
www.americanbankingnews.com - March 6 at 9:43 AM
General American Investors Co. Inc. Sells 37,708 Shares of Kindred Biosciences Inc (KIN)General American Investors Co. Inc. Sells 37,708 Shares of Kindred Biosciences Inc (KIN)
www.americanbankingnews.com - March 6 at 9:04 AM

SEC Filings

Kindred Biosciences (NASDAQ:KIN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kindred Biosciences (NASDAQ:KIN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kindred Biosciences (NASDAQ KIN) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.